Global Cancer Janus Kinase Inhibitors Market Opportunity and Clinical Trial Insight 2023

For Report Sample Contact: neeraj@kuickresearch.com

 

Report Weblink: https://www.kuickresearch.com/report-global-cancer-janus-kinase-inhibitors-market-opportunity-and-clinical-trial-insight-2023.php

 

Table of Contents

 

1. Prologue to JAK/STAT Pathway

  1.1 Overview

  1.2 Categorization of JAK/STAT Inhibitors in Cancer Therapeutics

2. Role of JAK/STAT Pathway in Tumor Formation

3. JAK/STAT Inhibitors: Modern Therapeutics for Effective Cancer Management

4. Understanding the Targets for Inhibition: An Insight into JAK and STAT Proteins

  4.1 Structure and Significance

    4.1.1 Janus Kinases: A Novel Cytokine Receptor

    4.1.2 STAT Proteins: The Signal Generators for Transcription

  4.2 Importance of Modulation of JAK/STAT in a Healthy Cell

5. Mechanism of Action of JAK/STAT Inhibitors

6. Identification of Active Target in Tumor Cells for JAK/STAT Inhibition

  6.1 Cell Based Assays

  6.2 Biochemical Assays

7. Need and Superiority of JAK/STAT Inhibitors: Its Importance in Modern Cancer Therapy

8. JAK/STAT Inhibitors in Cancer Therapy

  8.1 Hematological Malignancies

    8.1.1 Myelofibrosis

    8.1.2 Acute Lymphoblastic Leukemia

    8.1.3 Polycythemia Vera

    8.1.4 Primary thrombocythemia

  8.2 Solid Tumors

    8.2.1 Lung Cancer

    8.2.2 Ovarian Cancer

    8.2.3 Breast Cancer

    8.2.4 Pancreatic Cancer

    8.2.5 Hepatocellular Carcinoma

    8.2.6 Colorectal cancer

    8.2.7 Head and Neck Squamous Cell Carcinoma

    8.2.8 Prostate Cancer

    8.2.9 Glioblastoma

    8.2.10 Other Solid Tumors

9. Cancer JAK/STAT Inhibitor Drugs

  9.1 Approved Drugs

    9.1.1 Ruxolitinib

  9.2 Promising Candidates in the Clinical Pipeline

    9.2.1 Momelotinib

    9.2.2 Lestaurtinib

    9.2.3 Pacritinib

10. Global Cancer JAK/STAT Inhibitor Market Outlook

  10.1 Current Scenario

  10.2 Clinical Pipeline Overview

11. Global Cancer JAK/STAT Inhibitor Therapy Price Analysis

  11.1 Analyzing the Cost of Available JAK/STAT Inhibitor

  11.2 Comparative Price Analysis of JAK/STAT Inhibitors and Best Available Therapy

  11.3 Comparative Price Analysis of JAK/STAT Inhibitors and Conventional Cancer Therapies

  11.4 Comparative Price Analysis of JAK/STAT Inhibitors and Newly Approved Anti-Cancer Therapeutics

12. Global Cancer JAK/STAT Inhibitor Market Dynamics

  12.1 Favorable Factors for Cancer JAK/STAT Inhibitors Market

    12.1.1 Elevation in Disease Burden

    12.1.2 Unmet Medical Need

    12.1.3 Advancement in Technology

    12.1.4 Strong Clinical Pipeline

    12.1.5 Orphan Drug Status to JAK/STAT Inhibitors

    12.1.6 Commercial Success of Ruxolitinib

  12.2 Market challenges for Cancer JAK/STAT Inhibitors

    12.2.1 Scientific Limitations and the Number of Side Effects

    12.2.2 Clinical Hold on Pacritinib

    12.2.3 Tedious approval process

13. Global Cancer JAK/STAT Inhibitor Market Future Outlook

14. Global Cancer Janus Kinase Inhibitors Clinical Pipeline by Company and Phase

  14.1 Research

  14.2 Preclinical

  14.3 Phase-I

  14.4 Phase-I/II

  14.5 Phase-II

  14.6 Phase-III

  14.7 Preregistration

15. Marketed Cancer Janus Kinase Inhibitors Clinical Insight by Company

  15.1 Ruxolitinib (Jakafi and Jakavi)

16. Suspended Cancer Janus Kinase Inhibitors in Clinical Pipeline by Company and Phase

  16.1 No Development Reported

  16.2 Discontinued

17. Competitive Landscape

  17.1 Abbott Laboratories

  17.2 Asana Biosciences

  17.3 Astra Zeneca

  17.4 Celon Pharmaceuticals

  17.5 Dynamic Pharma

  17.6 Eli Lilly

  17.7 Gilead Sciences

  17.8 Hanmi Pharmaceuticals

  17.9 Incyte

  17.10 Kyowa Hakko

  17.11 Moleculin

  17.12 Pfizer

  17.13 PIQUR Therapeutics

  17.14 Portola Pharmaceuticals

  17.15 S*BIO

 

Figure 1-1: Conventional Approaches for Treating Cancer

Figure 1-2: Major Limitations of Conventional Cancer Therapies

Figure 1-3: Modern Approach in Cancer Therapy

Figure 1-4: Major Types of Cancer Treatment Modalities

Figure 1-5: Categorization of JAK Inhibitors in Targeted Therapies

Figure 3-1: Advanced Approaches for the Development of JAK/STAT Inhibitors

Figure 4-1: Architecture of the Structure of Janus Kinase

Figure 4-2: Cis Mode of Activation of Janus Kinase

Figure 4-3: Trans Mode of Activation of Janus Kinase

Figure 4-4: Architecture of the Structure of STAT Proteins

Figure 4-5: Activation of STAT Proteins

Figure 4-6: Natural Inhibitors of JAK/STAT Signaling Pathway

Figure 5-1: JAK/STAT Signaling Pathway in Normal Human Cell

Figure 5-2: JAK/STAT Pathway in Hematological Cancers

Figure 5-3: Mechanism of Action of JAK inhibitors

Figure 6-1: Technologies Used For Diagnosing JAK/STAT Pathway in Tumor Cells

Figure 7-1: Advanced Features of JAK/STAT Inhibitors in Cancer Therapy

Figure 8-1: JAK/STAT Mutations in Hematological Malignancies

Figure 9-1: Target and Effects of Ruxolitinib

Figure 9-2: Impact of Ruxolitinib on Change in Mean Spleen Size

Figure 10-1: Global Prevalence – Myelofibrosis Patients (Numbers), 2015-17

Figure 10-2: Global Prevalence – Polycythemia Vera Patients (Numbers), 2015-17

Figure 10-3 Global Prevalence – Primary Thrombocythemia Patients (Numbers), 2015-17

Figure 10-4 : Global- Ruxolitinib Revenue for Myelofibrosis (US$ Million), 2015-2017

Figure 10-5: Global – Ruxolitinib Revenue for Polycythemia Vera (US$ Million), 2015-2017

Figure 10-6: Global- Ruxolitinib Revenue for Primary Thrombocythemia (US$ Million), 2015-2017

Figure 10-7: Global- Ruxolitinib Revenue by Hematological Malignancies (%), 2016

Figure 10-8: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (%), 2017 till 2023

Figure 10-9: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (Number), 2017 till 2023

Figure 10-10: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (%), 2017 till 2023

Figure 10-11: Global Janus Kinase Inhibitors Cancer Clinical Pipeline by Phase (Number), 2017 till 2023

Figure 11-1: Ruxolitinib andndash; Average Per Tablet and Packet Cost Analysis (US$)

Figure 11-2: Ruxolitinib andndash; Average and Lifetime Treatment Cost Analysis (US$)

Figure 11-3: Global- Average Price of Ruxolitinib Treatment (US$/Month), 2015-2017

Figure 11-4: Survival Rate of Myelofibrosis Patients Undergoing Ruxolitinib Treatment v/s Best Available Therapy

Figure 11-5: Global – Average Lifetime Expenditure of Myelofibrosis Patient (US$)

Figure 11-6: Global – Average Lifetime Drug and Resource Cost (US$)

Figure 11-7: Global – Average Cost of Complete Treatment of Myelofibrosis Patient (US$)

Figure 11-8: Quality Adjusted Life Years for Ruxolitinib and Best Available Therapy for Myelofibrosis

Figure 11-9: Average Cost of JAK/STAT Inhibitors and Conventional Therapies for Cancer (US$/Month)

Figure 11-10: Complete Treatment Cost of JAK/STAT Inhibitors and Monoclonal Antibody Drug (US$)

Figure 11-11: Treatment Cost of JAK/STAT Inhibitors and CAR-T Cell Therapy for Cancer (US$)

Figure 11-12: Treatment Cost of JAK/STAT Inhibitors and Other Small Molecule Cancer Drugs (US$)

Figure 12-1: Global andndash; Cancer JAK/STAT Inhibitor Market Drivers

Figure 12-2: Global – Challenges for Cancer JAK/STAT Inhibitors Market

Figure 13-1: Global- Cancer JAK/STAT Inhibitors Market Opportunity (US$ Billion), 2018-2023

Table 2-1: JAK Mutations in Cancers

Table 2-2: STAT Mutations in Cancers

Table 11-1: Ruxolitinib Price Analysis